Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
$20.34
-0.4%
$18.04
$15.45
$35.84
$589.57M1.1425,501 shs353,247 shs
DermTech, Inc. stock logo
DMTK
DermTech
$0.19
$0.09
$3.90
$3.29M2.481.07 million shs3.66 million shs
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
$19.91
+0.2%
$20.03
$14.57
$25.11
$605.22M1.04285,607 shs211,894 shs
Genetron Holdings Limited stock logo
GTH
Genetron
$4.03
$3.98
$2.08
$4.05
$127.27M0.5151,662 shs412,603 shs
RadNet, Inc. stock logo
RDNT
RadNet
$55.62
-2.3%
$56.28
$45.00
$93.65
$4.27B1.41682,058 shs720,330 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-0.39%+6.16%+27.36%+0.74%-4.01%
DermTech, Inc. stock logo
DMTK
DermTech
0.00%0.00%0.00%0.00%-38.60%
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
+0.15%+2.00%-3.40%+13.00%-0.65%
Genetron Holdings Limited stock logo
GTH
Genetron
0.00%0.00%0.00%-0.12%-0.12%
RadNet, Inc. stock logo
RDNT
RadNet
-2.27%-0.29%-3.74%+5.92%-5.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
2.6908 of 5 stars
3.54.00.00.01.62.50.0
DermTech, Inc. stock logo
DMTK
DermTech
N/AN/AN/AN/AN/AN/AN/AN/A
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
3.4292 of 5 stars
2.31.00.04.12.03.30.6
Genetron Holdings Limited stock logo
GTH
Genetron
N/AN/AN/AN/AN/AN/AN/AN/A
RadNet, Inc. stock logo
RDNT
RadNet
4.2158 of 5 stars
3.82.00.04.62.32.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
3.00
Buy$37.0081.91% Upside
DermTech, Inc. stock logo
DMTK
DermTech
0.00
N/AN/AN/A
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
2.50
Moderate Buy$24.0020.54% Upside
Genetron Holdings Limited stock logo
GTH
Genetron
0.00
N/AN/AN/A
RadNet, Inc. stock logo
RDNT
RadNet
3.50
Strong Buy$69.6025.13% Upside

Current Analyst Ratings Breakdown

Latest GTH, CSTL, FLGT, RDNT, and DMTK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/13/2025
RadNet, Inc. stock logo
RDNT
RadNet
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy ➝ Buy$69.00
6/12/2025
RadNet, Inc. stock logo
RDNT
RadNet
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy ➝ Strong-Buy
5/21/2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$44.00 ➝ $40.00
5/6/2025
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$16.00 ➝ $23.00
5/6/2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$40.00 ➝ $35.00
5/6/2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$42.00 ➝ $37.00
5/5/2025
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$24.00 ➝ $25.00
4/11/2025
RadNet, Inc. stock logo
RDNT
RadNet
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$88.00 ➝ $74.00
(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
$332.07M1.77$0.98 per share20.75$16.28 per share1.25
DermTech, Inc. stock logo
DMTK
DermTech
$15.66M0.00N/AN/A$1.67 per share0.00
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
$283.47M2.14N/AN/A$36.92 per share0.54
Genetron Holdings Limited stock logo
GTH
Genetron
$94.34M1.35N/AN/A$2.63 per share1.53
RadNet, Inc. stock logo
RDNT
RadNet
$1.83B2.28$3.40 per share16.34$15.31 per share3.63
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
$18.25M-$0.19N/AN/AN/A-1.46%3.41%2.95%8/4/2025 (Estimated)
DermTech, Inc. stock logo
DMTK
DermTech
-$100.89M-$2.70N/AN/AN/A-572.19%-138.79%-68.96%N/A
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
-$42.71M-$1.33N/AN/AN/A-13.94%-2.19%-2.02%8/1/2025 (Estimated)
Genetron Holdings Limited stock logo
GTH
Genetron
-$117.21MN/A0.00N/AN/AN/AN/AN/A
RadNet, Inc. stock logo
RDNT
RadNet
$2.79M-$0.43N/A104.94N/A-1.73%1.41%0.48%8/6/2025 (Estimated)

Latest GTH, CSTL, FLGT, RDNT, and DMTK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/5/2025Q1 2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-$0.08-$0.20-$0.12-$0.90$80.40 million$87.99 million
5/2/2025Q1 2025
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
-$0.18$0.04+$0.22-$0.37$71.26 million$73.46 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
N/AN/AN/AN/AN/A
DermTech, Inc. stock logo
DMTK
DermTech
N/AN/AN/AN/AN/A
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
N/AN/AN/AN/AN/A
Genetron Holdings Limited stock logo
GTH
Genetron
N/AN/AN/AN/AN/A
RadNet, Inc. stock logo
RDNT
RadNet
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
0.02
9.37
9.19
DermTech, Inc. stock logo
DMTK
DermTech
N/A
3.53
3.46
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
N/A
6.32
6.32
Genetron Holdings Limited stock logo
GTH
Genetron
N/AN/AN/A
RadNet, Inc. stock logo
RDNT
RadNet
0.87
2.01
2.01

Institutional Ownership

CompanyInstitutional Ownership
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
92.60%
DermTech, Inc. stock logo
DMTK
DermTech
20.45%
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
48.06%
Genetron Holdings Limited stock logo
GTH
Genetron
10.74%
RadNet, Inc. stock logo
RDNT
RadNet
77.90%

Insider Ownership

CompanyInsider Ownership
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
7.20%
DermTech, Inc. stock logo
DMTK
DermTech
5.10%
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
33.11%
Genetron Holdings Limited stock logo
GTH
Genetron
N/A
RadNet, Inc. stock logo
RDNT
RadNet
5.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
54028.87 million26.79 millionOptionable
DermTech, Inc. stock logo
DMTK
DermTech
26034.96 million33.18 millionOptionable
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
1,31330.44 million20.36 millionOptionable
Genetron Holdings Limited stock logo
GTH
Genetron
99331.62 millionN/ANot Optionable
RadNet, Inc. stock logo
RDNT
RadNet
11,02175.03 million70.83 millionOptionable

Recent News About These Companies

RadNet (NASDAQ:RDNT) Upgraded at Wall Street Zen

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Castle Biosciences stock logo

Castle Biosciences NASDAQ:CSTL

$20.34 -0.08 (-0.39%)
Closing price 07/1/2025 04:00 PM Eastern
Extended Trading
$20.37 +0.03 (+0.15%)
As of 07/1/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

DermTech stock logo

DermTech NASDAQ:DMTK

DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.

Fulgent Genetics stock logo

Fulgent Genetics NASDAQ:FLGT

$19.91 +0.03 (+0.15%)
Closing price 07/1/2025 04:00 PM Eastern
Extended Trading
$19.91 0.00 (0.00%)
As of 07/1/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

Genetron stock logo

Genetron NASDAQ:GTH

Genetron Holdings Limited, a precision oncology platform company, focuses on cancer management by utilizing technologies in molecular biology and data science in the People's Republic of China. It offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. The company also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. Genetron Holdings Limited was founded in 2013 and is headquartered in Beijing, the People's Republic of China.

RadNet stock logo

RadNet NASDAQ:RDNT

$55.62 -1.29 (-2.27%)
Closing price 07/1/2025 04:00 PM Eastern
Extended Trading
$55.62 +0.01 (+0.01%)
As of 07/1/2025 06:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.